Transforming growth factor-β inhibition attenuates pulmonary arterial hypertension in rats

International Journal of Clinical and Experimental Medicine

Volumn 3, Issue 4, 2010, Pages 332-340

  Megalou, Aikaterini J ^a   Glava, Chryssoula ^b   Oikonomidis, Dimitrios L ^a   Vilaeti, Agapi ^a   Agelaki, Maria G ^a   Baltogiannis, Giannis G ^a   Papalois, Apostolos ^c,d   Vlahos, Antonios P ^e   Kolettis, Theofilos M ^a,d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ELPEN Research Laboratory   (Greece)

^d Cardiovascular Research Institute   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Exercise tolerance; Pulmonary arterial hypertension; Pulmonary vascular remodeling; Transforming growth factor

Indexed keywords

MONOCROTALINE; T 9429; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKENING; ARTERY MEDIA; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; EXERCISE; EXERCISE TOLERANCE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HEART RIGHT VENTRICLE SYSTOLIC PRESSURE; HISTOPATHOLOGY; LUNG HEMODYNAMICS; NONHUMAN; OSMOTIC MINIPUMP; PULMONARY HYPERTENSION; RAT;

RATTUS; RATTUS NORVEGICUS;

EID: 78649734109     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sastry BK. Pharmacologic treatment for pulmonary arterial hypertension. Curr Opin Cardiol 2006; 21: 561-568.
2. Farber HW and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
3. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF and Rabinovitch M. Cellular and molecular pathobiology of pul monary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
4. Roberts AB and Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993; 8: 1-9.
5. Khan R, Agrotis A and Bobik A. Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury. Cardiovasc Res 2007; 74: 223-234.
6. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK and Morrell NW. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009; 119: 566-576.
7. Perkett EA, Lyons RM, Moses HL, Brigham KL and Meyrick B. Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. J Clin Invest 1990; 86: 1459-1464.
8. Botney MD, Bahadori L and Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factorbeta. Am J Pathol 1994; 144: 286-295.
9. Harrison RE, Flanagan JA, Sankelo M, Abdalla SA, Rowell J, Machado RD, Elliott CG, Robbins IM, Olschewski H, McLaughlin V, Gruenig E, Kermeen F, Halme M, Raisanen-Sokolowski A, Laitinen T, Morrell NW and Trembath RC. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003; 40: 865-871.
10. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell NW, Berg J, Manes A, McGaughran J, Pauciulo M and Wheeler L. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325-334.
11. Yeager ME, Golpon HA, Voelkel NF and Tuder RM. Microsatellite mutational analysis of endothelial cells within plexiform lesions from patients with familial, pediatric, and sporadic pulmonary hypertension. Chest 2002; 121: 61S.
12. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK and Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001; 104: 790-795.
13. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC and Morrell NW. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002; 11: 1517-1525.
14. Geraci MW, Hoshikawa Y, Yeager M, Golpon H, Gesell T, Tuder RM and Voelkel NF. Gene expression profiles in pulmonary hypertension. Chest 2002; 121: 104S-105S.
15. Zakrzewicz A, Kouri FM, Nejman B, Kwapiszewska G, Hecker M, Sandu R, Dony E, Seeger W, Schermuly RT, Eickelberg O and Morty RE. The transforming growth factor-beta/Smad2,3 signalling axis is impaired in experimental pulmonary hypertension. Eur Respir J 2007; 29: 1094-1104.
16. Arcot SS, Lipke DW, Gillespie MN and Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotalineinduced pulmonary hypertension. Biochem Pharmacol 1993; 46: 1086-1091.
17. Schulz KF and Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet 2002; 359: 515-519.
18. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M and Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Bmj 2010; 340: c869.
19. Altiere RJ, Olson JW and Gillespie MN. Altered pulmonary vascular smooth muscle responsiveness in monocrotaline-induced pulmonary hypertension. J Pharmacol Exp Ther 1986; 236: 390-395.
20. T9429 Datasheet (2009). In http://wwwsigmaaldrichcom/etc/medialib/docs/Sigma/Datasheet/t9429datPar0001Filetmp/t9429datpdf.
21. Andarawewa KL, Paupert J, Pal A and Barcellos-Hoff MH. New rationales for using TGFbeta inhibitors in radiotherapy. Int J Radiat Biol 2007; 83: 803-811.
22. Furlani D, Klopsch C, Gabel R, Ugurlucan M, Pittermann E, Klee D, Wagner K, Li W, Wang W, Ong LL, Nizze H, Titze U, Lutzow K, Lendlein A, Steinhoff G and Ma N. Intracardiac erythropoietin injection reveals antiinflammatory potential and improved cardiac functions detected by Forced Swim Test. Transplant Proc 2008; 40:962-966.
23. Girgis RE, Li D, Zhan X, Garcia JGN, Tuder RM, Hassoun PM and Johns RA. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285: H938-H945.
24. Kolettis T, Vlahos AP, Louka M, Hatzistergos KE, Baltogiannis GG, Agelaki MM, Mitsi A and Malamou-Mitsi V. Characterisation of a rat model of pulmonary arterial hypertension. Hellenic J Cardiol 2007; 48: 206-210.
25. Everett AD, Le Cras TD, Xue C and Johns RA. eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow. Am J Physiol 1998; 274: L1058-1065.
26. Meyrick B and Reid L. Ultrastructural features of the distended pulmonary arteries of the normal rat. Anat Rec 1979; 193: 71-97.
27. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118: 2372-2379.
28. Padgett RW, Das P and Krishna S. TGF-beta signaling, Smads, and tumor suppressors. Bioessays 1998; 20: 382-390.
29. Massague J and Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-644.
30. Tanaka Y, Bernstein ML, Mecham RP, Patterson GA, Cooper JD and Botney MD. Site-specific responses to monocrotaline-induced vascular injury: evidence for two distinct mechanisms of remodeling. Am J Respir Cell Mol Biol 1996; 15: 390-397.
31. Kimura H, Kasahara Y, Kurosu K, Sugito K, Takiguchi Y, Terai M, Mikata A, Natsume M, Mukaida N, Matsushima K and Kuriyama T. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1998; 78: 571-581.
32. Tuder RM, Marecki JC, Richter A, Fijalkowska I and Flores S. Pathology of pulmonary hypertension. Clin Chest Med 2007; 28: 23-42, vii.
33. Archer SL. Diversity of phenotype and function of vascular smooth muscle cells. J Lab Clin Med 1996; 127: 524-529.
34. Frid MG, Aldashev AA, Dempsey EC and Stenmark KR. Smooth muscle cells isolated from discrete compartments of the mature vascular media exhibit unique phenotypes and distinct growth capabilities. Circ Res 1997; 81: 940-952.
35. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S and ten Dijke P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003; 12: 817-828.
36. Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, Shimoda LA, Neptune E, Higgins L, Murphy A, Chakravarty S, Protter A, Sehgal PB, Champion HC and Tuder RM. Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 2008; 177: 896-905.
37. Kittipovanonth M, Bellavia D, Chandrasekaran K, Villarraga HR, Abraham TP and Pellikka PA. Doppler myocardial imaging for early detection of right ventricular dysfunction in patients with pulmonary hypertension. J Am Soc Echocardiogr 2008; 21: 1035-1041.
38. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A and Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008; 371:2093-2100.